scholarly journals Intravenous Immune Globulin Uses in the Fetus and Neonate: A Review

Antibodies ◽  
2020 ◽  
Vol 9 (4) ◽  
pp. 60
Author(s):  
Mahdi Alsaleem
Keyword(s):  
Immune Globulin ◽  
Adverse Reactions ◽  
Clinical Evidence ◽  
Intravenous Immune Globulin ◽  
Consensus Guidelines ◽  
Neonatal Hemochromatosis ◽  
Healthy Donors ◽  
Pediatric Populations ◽  
Fetus And Neonate ◽  
Neonatal Population

Intravenous immune globulin (IVIG) is made after processing plasma from healthy donors. It is composed mainly of pooled immunoglobulin and has clinical evidence-based applications in adult and pediatric populations. Recently, several clinical applications have been proposed for managing conditions in the neonatal population, such as hemolytic disease of the newborn, treatment, and prophylaxis for sepsis in high-risk neonates, enterovirus parvovirus and COVID-19 related neonatal infections, fetal and neonatal immune-induced thrombocytopenia, neonatal hemochromatosis, neonatal Kawasaki disease, and some types of immunodeficiency. The dosing, mechanism of action, effectiveness, side effects, and adverse reactions of IVIG have been relatively well studied in adults but are not well described in the neonatal population. This review aims to provide the most recent evidence and consensus guidelines about the use of IVIG in the fetus and neonate.

Intravenous Immune Globulin in the Therapy of Myocarditis and Acute Cardiomyopathy

Circulation ◽  
1997 ◽  
Vol 95 (11) ◽  
pp. 2476-2478 ◽  
Author(s):  
Dennis M. McNamara ◽  
Warren D. Rosenblum ◽  
Karen M. Janosko ◽  
Mary K. Trost ◽  
Flordeliza S. Villaneuva ◽  
...  
Keyword(s):  
Immune Globulin ◽  
Intravenous Immune Globulin

scholarly journals T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab

2021 ◽  
Vol 9 (5) ◽  
pp. e002521
Author(s):  
Sean Hammond ◽  
Anna Olsson-Brown ◽  
Joshua Gardner ◽  
Paul Thomson ◽  
Serat-E Ali ◽  
...  
Keyword(s):  
Contrast Media ◽  
Adverse Reactions ◽  
Stevens Johnson Syndrome ◽  
Iodinated Contrast ◽  
Immune Mediated ◽  
Johnson Syndrome ◽  
Healthy Donors ◽  
Concomitant Medications

Many adverse reactions associated with immune checkpoint inhibitor (ICI) treatments are immunologically driven and may necessitate discontinuation of the ICI. Herein, we present a patient who had been administered the radio contrast media amidotrizoate multiple times without issue but who then developed a Stevens-Johnson syndrome reaction after coadministration of atezolizumab. Causality was confirmed by a positive re-challenge with amidotrizoate and laboratory investigations that implicated T cells. Importantly, the introduction of atezolizumab appears to have altered the immunologic response to amidotrizoate in terms of the tolerance–elicitation continuum. Proof of concept studies demonstrated enhancement of recall responses to a surrogate antigen panel following in-vitro (healthy donors) and in-vivo (ICI patients) administrations of ICIs. Our findings highlight the importance of considering all concomitant medications in patients on ICIs who develop immune-mediated adverse reactions. In the event of some immune-related adverse reactions, it may be critical to identify the culprit antigen-forming entity that the ICIs have altered the perception of rather than simply attribute causality to the ICI itself in order to optimize both patient safety and treatment of malignancies.

Treatment of Stevens-Johnson Syndrome With Pooled Human Intravenous Immune Globulin

1995 ◽  
Vol 34 (1) ◽  
pp. 48-51 ◽  
Author(s):  
Asha Moudgil ◽  
Shimshon Porat ◽  
Philip Brunnel ◽  
Stanley C. Jordan
Keyword(s):  
Immune Globulin ◽  
Intravenous Immune Globulin ◽  
Stevens Johnson Syndrome ◽  
Johnson Syndrome

Intravenous immunoglobulin utilization in the Canadian Atlantic provinces: a report of the Atlantic Collaborative Intravenous Immune Globulin Utilization Working Group

Transfusion ◽  
2007 ◽  
Vol 47 (11) ◽  
pp. 2072-2080 ◽  
Author(s):  
Maggie M. Constantine ◽  
Wanda Thomas ◽  
Lucinda Whitman ◽  
Eiad Kahwash ◽  
Sean Dolan ◽  
...  
Keyword(s):  
Intravenous Immunoglobulin ◽  
Immune Globulin ◽  
Working Group ◽  
Intravenous Immune Globulin

Abstract 135: Effectiveness Of Live Vaccines Following Intravenous Immune Globulin Therapy During The Convalescent Phase Of Kawasaki Disease Using The Schedule Recommended In Japan

Circulation ◽  
2015 ◽  
Vol 131 (suppl_2) ◽  
Author(s):  
Yoshihiko Morikawa ◽  
Masaru Miura ◽  
Hiroshi Sakakibara ◽  
Keyword(s):  
Kawasaki Disease ◽  
Immune Globulin ◽  
Past History ◽  
The United States ◽  
Vaccination Schedule ◽  
Vaccine Virus ◽  
Intravenous Immune Globulin ◽  
Serious Adverse Events ◽  
Live Virus ◽  
Varicella Zoster

Background: There are differences between Japan and the United States regarding recommended timing of live virus vaccinations after treatment of Kawasaki disease patients with intravenous immune globulin (IVIG): 6 months in Japan and 11 months in the U.S. The prevalence of antibodies to these vaccines using either vaccination schedule remains undetermined. Objective: The present study aimed to evaluate the effectiveness of the live virus vaccination schedule for Kawasaki disease recommended in Japan. Methods: This was a prospective observational study. Kawasaki disease patients aged 6 months and older without past history of or vaccination against measles, rubella, varicella-zoster (VZ), or mumps were enrolled. The children were vaccinated against measles, rubella, VZ, and mumps 6 months after IVIG. Serologic tests for IgG-class specific antibodies to each vaccine virus were performed prior to IVIG; 2 days, 3 months, and 6 months after IVIG, and 3 months after vaccination. The primary outcome was seroprevalence of positive antibodies, which was defined as serum concentration more than 4 IU/mL. Results: A total of 24 children (mean month age 16.8 ± 2.7 at vaccinations, 70.8% male) were enrolled. The rate of measles, rubella, VZ, and mumps seropositivity was 12.5% (3/24), 0% (0/24), 12.5% (3/24), and 0% (0/24), respectively, just before vaccination. The rate increased to 91.7% (22/24), 87.5% (21/24), 20.8% (5/24), and 8.3% (2/24), respectively, 3 months after vaccination. There were no serious adverse events. Conclusions: Use of the Japanese vaccination schedule led to extremely low seroprevalence of VZ and mumps antibodies but acceptable seroprevalence of measles and rubella antibodies. This study is ongoing and more cases (up to 30, the target sample size) are needed before the appropriateness of the timing of vaccination in Japan can be discussed.

Sign in / Sign up

Export Citation Format

Share Document